Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy

Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorGan & Lee Pharmaceuticals.

About this trial

This study is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of GZR18 injection in obese subjects with moderate to severe obstructive sleep apnea who are unable or unwilling to undergo positive airway pressure (PAP) therapy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Subject is aged ≥18 years at the time of signing the informed consent form.

Body mass index (BMI) is ≥28 kg/m² at both screening and randomization.

Subject has a documented history of at least one unsuccessful attempt at weight loss through dietary control prior to screening, and has had <5% change in body weight during the 12 weeks prior to screening.

Subject has been diagnosed with obstructive sleep apnea (OSA) , and has a centrally assessed apnea-hypopnea index (AHI) ≥15 events/hour on polysomnography (PSG) at screening.

Disqualifiers

Known or suspected hypersensitivity to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or any of their excipients, or presence of a contraindication to GLP-1 RA use.

History of any type of diabetes mellitus (history of gestational diabetes is permitted).

Has undergone or plans to undergo during the study period surgical or device-based obesity treatment (exceptions: acupuncture, liposuction, or abdominal fat removal performed >1 year prior to screening; prior device-based obesity treatment is acceptable if the device was removed >1 year before screening).

Secondary obesity due to disease, medication, or other causes (e.g., Cushing's syndrome, Prader-Willi syndrome, monogenic obesity, or obesity secondary to hypothalamic/pituitary injury).

Trial design

Design model

Parallel

Treatments tested in this trial

  • Placebo

    Drug

    subcutaneous administration

  • GZR18 injection

    Drug

    subcutaneous administration

Treatment groups

140 Participants
are divided into 2 treatment groups
Group A: GZR18 injectionExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change from baseline in Apnea-Hypopnea Index (AHI) after 52 weeks of treatment

Time frame
52 weeks

Secondary outcomes

1

Percentage change in AHI from baseline

Time frame
52weeks
2

Proportion of participants with ≥50% reduction in AHI from baseline

Time frame
52 weeks
3

Proportion of participants achieving the following criteria:AHI < 5; or 5 ≤ AHI ≤ 14 and Epworth Sleepiness Scale (ESS) score ≤ 10

Time frame
52 weeks
4

Percentage change in body weight from baseline

Time frame
52 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: